<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03818815</url>
  </required_header>
  <id_info>
    <org_study_id>OP0201-C-006</org_study_id>
    <nct_id>NCT03818815</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability and Efficacy of OP0201 as an Adjunct Treatment for Acute Otitis Media in Infants and Children Aged 6 to 24 Months</brief_title>
  <official_title>A Study to Assess the Safety, Tolerability and Efficacy of OP0201 as an Adjunct Treatment for Acute Otitis Media in Infants and Children Aged 6 to 24 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novus Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novus Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop a better understanding of the safety, tolerability
      and efficacy of intranasal OP0201 as an adjunct treatment to oral antibiotics for the
      treatment of Acute Otitis Media (AOM) in infants and children.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 21, 2019</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Safety (Adverse Events)</measure>
    <time_frame>Days 1-28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Efficacy (Otoscopy)</measure>
    <time_frame>Day 4</time_frame>
    <description>Proportion of study participants with bulging tympanic membrane</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Efficacy (Otoscopy)</measure>
    <time_frame>Day 12</time_frame>
    <description>Proportion of study participants with no middle ear effusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Efficacy (Tympanometry)</measure>
    <time_frame>Days 4, 12 and 28</time_frame>
    <description>Proportion of study participants with normal tympanogram (Type A)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Efficacy (AOM-SOS Scale)</measure>
    <time_frame>Days 4, 12, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Efficacy (AOM relapse)</measure>
    <time_frame>Days 12-17</time_frame>
    <description>Proportion of study participants with AOM relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Efficacy (AOM recurrence)</measure>
    <time_frame>Days 17-28</time_frame>
    <description>Proportion of study participants with AOM recurrence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Acute Otitis Media</condition>
  <arm_group>
    <arm_group_label>Drug: OP0201 + Antibiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OP0201 20mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Placebo +Antibiotics</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 0 mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OP0201 20mg per day+Amoxicillin-clavulanate</intervention_name>
    <description>OP0201 20mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days</description>
    <arm_group_label>Drug: OP0201 + Antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 0mg per day+Amoxicillin-clavulanate</intervention_name>
    <description>Placebo 0mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days</description>
    <arm_group_label>Placebo Comparator: Placebo +Antibiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria includes but is not limited to:

          1. Male and female infants and children aged ≥6 months to ≤24 months

          2. Diagnosis of Acute Otitis Media (AOM) - moderate to severe bulging of the TM or mild
             bulging of TM and recent [less than 48 hours] onset of ear pain or intense erythema of
             the TM

          3. Score of 5 or more on the 5 question version of AOM-SOS scale1

          4. Written informed consent by the child's legal guardian and their willingness to ensure
             that study instructions are followed, all study-related visits are attended, that
             treatment administration is given, and Parent/Caregiver assessments are recorded
             according to the study protocol.

          5. Intact tympanic membrane (TM) in both ears (e.g., no perforation)

        Exclusion Criteria includes but is not limited to:

          1. Allergy to penicillin or cephalosporin

          2. History or presence of immunodeficiency disorders

          3. Antimicrobial therapy within the 3 days (i.e., 72 hours) prior to Day 1

          4. Craniofacial abnormalities (e.g., cleft palate or Down's Syndrome) that may interfere
             with Eustachian tube function

          5. Disorders with decreased mucociliary clearance or higher viscosity of the mucous
             (e.g., cystic fibrosis, primary ciliary dyskinesia, Kartagener's syndrome)

          6. Clinically relevant blockage of 1 or both nasal passages, as determined by the
             investigator's medical judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburgh - General Academic Pediatrics Oakland Medical Building</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novustherapeutics.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 22, 2019</study_first_submitted>
  <study_first_submitted_qc>January 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2019</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>July 1, 2020</submitted>
    <returned>July 16, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

